Minirin Melt60 mcg

Minirin Melt is a synthetic analog of the natural hormone vasopressin (antidiuretic hormone). It is prescribed for the following indications, which vary in strength of evidence:

Established/approved uses

• Central diabetes insipidus — as antidiuretic replacement therapy to control excessive thirst and urination caused by deficient endogenous vasopressin.
• Temporary polyuria and polydipsia following head trauma or pituitary surgery.
• Primary nocturnal enuresis (bedwetting) in children aged 6 years and older, used alone or together with behavioral measures; oral tablet or sublingual formulations of Minirin Melt are generally preferred over intranasal spray for this indication (see Precautions and Warnings).

Specialist-guided / hemostatic uses (higher-dose injectable or concentrated intranasal formulations)

• To temporarily raise plasma factor VIII and von Willebrand factor levels in selected patients with mild haemophilia A or type 1 von Willebrand disease, to control or prevent bleeding around minor surgery or dental procedures. Response varies by patient and requires factor-level testing and haematology specialist supervision.

Minirin Melt is not effective for nephrogenic diabetes insipidus.

Each formulation of Desmopressin Acetate contains desmopressin acetate as the active ingredient. Depending on the market, it is available as sublingual tablets (e.g., 60 mcg, 120 mcg), oral film-coated tablets (e.g., 0.1 mg, 0.2 mg), an oral solution, and, in some settings, as an intranasal spray or injectable solution for hospital/specialist use.

Minirin Melt is a synthetic structural analog of arginine vasopressin (antidiuretic hormone) with selective agonist activity at renal V2 receptors and, at higher doses, effects on coagulation factors. Compared with natural vasopressin, it has a longer duration of action, negligible pressor (V1) activity at antidiuretic doses, and no significant oxytocic activity. It is used to reduce excessive urination in diabetes insipidus and nocturnal enuresis, and, at higher doses, to raise clotting factor levels in selected bleeding disorders.

Minirin Melt belongs to the therapeutic class of antidiuretic hormone (vasopressin) analogues, classified under posterior pituitary hormones. At higher, hemostatic doses it is also used within the class of non-transfusional hemostatic agents for selected bleeding disorders.

Desmopressin Acetate acts as a selective agonist at vasopressin V2 receptors in the renal collecting ducts, increasing water reabsorption via aquaporin-2 channel insertion and producing an antidiuretic effect (reduced urine volume, increased urine osmolality) without a clinically significant pressor (V1-receptor) effect at usual doses. At the higher doses used for hemostasis, Desmopressin Acetate also stimulates release of endogenous factor VIII and von Willebrand factor from vascular endothelial storage sites, transiently raising plasma levels of these clotting factors and shortening bleeding time in appropriate patients.

After oral or sublingual administration, bioavailability is low (a small percentage of the dose) but sufficient for the drug's antidiuretic effect; onset of action is generally within 1-2 hours, with a duration of roughly 8-12 hours or longer, allowing once- to thrice-daily dosing depending on the indication and formulation.

Minirin Melt oral tablets should be taken on an empty stomach (at least 1 hour before or 2 hours after food) for consistent absorption. Sublingual tablets should be placed under the tongue and allowed to dissolve completely without chewing or swallowing whole. Injectable or intranasal formulations (where prescribed for hemostatic use) must be administered only by, or under the direct guidance of, a qualified healthcare professional. Fluid intake must be restricted around the time of dosing as instructed by the physician, and doses should not be doubled or skipped without medical advice.

The following interactions with Minirin Melt are clinically significant:

• Drugs that increase the risk of water retention/hyponatremia — including tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs), chlorpromazine, opioid analgesics, NSAIDs, carbamazepine, and lamotrigine — may potentiate the antidiuretic effect of Minirin Melt and increase the risk of hyponatremia and water intoxication when used together; concurrent use requires closer monitoring of serum sodium.
• Loperamide may increase plasma concentrations of oral Minirin Melt, potentially increasing the risk of water retention.
• Other drugs affecting the vasopressin system or renal water handling should be used cautiously and only under medical supervision alongside Minirin Melt.

Common side effects of Minirin Melt include headache, nausea, mild abdominal pain, nasal congestion or irritation (with intranasal use), and flushing. Less commonly, mild transient blood pressure changes may occur.

The most important serious adverse effect is hyponatremia (low blood sodium) and water intoxication, which can present as headache, nausea/vomiting, weight gain, confusion, and, if severe and untreated, seizures or coma (see Precautions and Warnings). Rare hypersensitivity/allergic reactions have also been reported.

Pregnancy: Minirin Melt has been assigned a legacy FDA Pregnancy Category B. Animal reproduction studies have not shown fetal harm, and available human data (including epidemiologic follow-up) have not shown an increased rate of birth defects, but there are no adequate and well-controlled studies in pregnant women. Minirin Melt should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; a physician should be consulted.

Lactation: It is not definitively known whether Minirin Melt is excreted in human breast milk in clinically significant amounts. Caution is advised, and a physician should be consulted before use of Minirin Melt while breastfeeding.

Fluid restriction is essential during and after each dose of Minirin Melt — patients and caregivers must limit fluid intake to what is needed to satisfy thirst, from about one hour before dosing until the following morning (or about 8 hours after dosing), because excess fluid intake combined with the antidiuretic effect of Minirin Melt substantially increases the risk of hyponatremia and water intoxication, which can be life-threatening.

Historical boxed warning (intranasal formulations, enuresis)

Hyponatremia and seizures have been reported with intranasal formulations of Minirin Melt used for primary nocturnal enuresis in children; because of this risk, oral (tablet or sublingual) formulations of Minirin Melt are now generally preferred over the intranasal route for this indication, and intranasal formulations are not recommended for enuresis.

Other precautions

• Use with caution in patients with cystic fibrosis, who have an increased risk of hyponatremia.
• Use with caution in elderly patients, who are at increased risk of hyponatremia and may need downward adjustment of fluid intake.
• Use with caution in patients with cardiovascular disease, hypertension, or conditions predisposing to fluid/electrolyte imbalance.
• Interrupt treatment temporarily during acute intercurrent illness associated with fluid or electrolyte imbalance (e.g., vomiting, diarrhea, fever) or during conditions of increased water intake (intense exercise, heat exposure).
• For the hemostatic indication, factor VIII/von Willebrand factor levels should be monitored, and repeated dosing may result in a diminished response (tachyphylaxis).

Overdosage of Minirin Melt can cause fluid retention and hyponatremia (water intoxication), with symptoms such as persistent headache, drowsiness, confusion, nausea and vomiting, rapid weight gain, decreased urine output, and, in severe cases, seizures. If overdose is suspected, seek immediate medical attention or contact emergency services/a poison control center. Management generally involves stopping Minirin Melt, restricting fluid intake, and supportive/symptomatic treatment under medical supervision; there is no specific antidote.

Store Minirin Melt at room temperature, below 30°C, protected from light and moisture. Do not freeze injectable or nasal-spray formulations of Minirin Melt unless otherwise directed. Keep all forms of Minirin Melt out of the reach and sight of children.

Renal impairment: Minirin Melt is contraindicated in moderate to severe renal impairment (creatinine clearance below approximately 50 mL/min) for the diabetes insipidus and enuresis indications, due to a reduced ability to excrete free water.

Hepatic impairment: No well-established dose adjustment is defined for Minirin Melt; use with caution and physician supervision.

Elderly: Increased risk of hyponatremia with Minirin Melt; fluid intake should be adjusted downward and serum sodium monitored, especially at the start of treatment.

Children: See Pediatric Uses.

Bleeding disorders (hemostatic use): Response to Minirin Melt varies by the specific type and severity of factor VIII deficiency or von Willebrand disease; use requires prior factor-level testing and hematology specialist guidance, and is not effective in severe haemophilia A or in von Willebrand disease types 2B or 3.

Duration of treatment with Minirin Melt depends on the indication. In central diabetes insipidus, treatment is typically long-term (often lifelong) as antidiuretic replacement therapy, with periodic reassessment of dose and serum sodium. In primary nocturnal enuresis, treatment is usually given for defined courses (e.g., around 3 months) with periodic breaks to reassess whether continued treatment with Minirin Melt is needed. For hemostatic use in bleeding disorders, Minirin Melt is typically used short-term, around planned procedures or bleeding episodes, under specialist direction. The treating physician should determine the appropriate duration in each case.

Antidiuretic hormone (vasopressin) analogues; posterior pituitary hormone replacements; non-transfusional hemostatic agents.

Desmopressin Acetate selectively stimulates renal V2 vasopressin receptors, increasing water reabsorption in the collecting ducts and concentrating urine, with minimal V1 (vasopressor) activity at antidiuretic doses. At higher doses, it also triggers release of stored factor VIII and von Willebrand factor from vascular endothelium, transiently improving hemostasis in appropriate bleeding disorders.

B

Minirin Melt is approved for use in children aged 4 years and older for central diabetes insipidus, and in children aged 6 years and older for primary nocturnal enuresis, using the lowest effective dose with close monitoring for hyponatremia (headache, nausea, vomiting, weight gain, confusion). Fluid intake in children must be carefully restricted around dosing times. Safety and efficacy of Minirin Melt for the hemostatic (bleeding disorder) indication in young children have not been as extensively established and should be guided by a pediatric hematology specialist. Intranasal formulations of Minirin Melt are not recommended for nocturnal enuresis in children because of the reported risk of hyponatremia and seizures with that route.